Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 7
1981 5
1982 7
1983 13
1984 16
1985 24
1986 13
1987 16
1988 38
1989 72
1990 90
1991 97
1992 108
1993 99
1994 120
1995 138
1996 131
1997 126
1998 124
1999 123
2000 131
2001 118
2002 130
2003 111
2004 111
2005 122
2006 120
2007 118
2008 115
2009 124
2010 123
2011 118
2012 137
2013 129
2014 136
2015 136
2016 108
2017 103
2018 90
2019 118
2020 122
2021 139
2022 104
2023 110
2024 110
2025 139
2026 68

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,186 results

Results by year

Filters applied: . Clear all
Page 1
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study.
Harada T, Osuga Y, Suzuki Y, Fujisawa M, Fukui M, Kitawaki J. Harada T, et al. Fertil Steril. 2022 Mar;117(3):583-592. doi: 10.1016/j.fertnstert.2021.11.013. Epub 2021 Dec 8. Fertil Steril. 2022. PMID: 34895700 Free article. Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of 40-mg relugolix (REL) compared with those of leuprorelin (LEU) in women with endometriosis-associated pain. DESIGN: Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study in Japanese patients. …
OBJECTIVE: To evaluate the efficacy and safety of 40-mg relugolix (REL) compared with those of leuprorelin (LEU) in women with endome …
Leuprorelin acetate in prostate cancer: a European update.
Persad R. Persad R. Int J Clin Pract. 2002 Jun;56(5):389-96. Int J Clin Pract. 2002. PMID: 12137449 Review.
This review provides an update on leuprorelin acetate, the world's most widely prescribed depot luteinising hormone-releasing hormone analogue. Leuprorelin acetate has been in clinical use in the palliative treatment of prostate cancer for more than 20 years, but ad …
This review provides an update on leuprorelin acetate, the world's most widely prescribed depot luteinising hormone-releasing hormone …
Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.
Chrisp P, Sorkin EM. Chrisp P, et al. Drugs Aging. 1991 Nov-Dec;1(6):487-509. doi: 10.2165/00002512-199101060-00008. Drugs Aging. 1991. PMID: 1794035 Review.
Leuprorelin (leuprolide acetate) is a synthetic analogue of gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH)] which initially stimulates luteinising hormone (LH) and hence testicular androgen release; continuous administration the …
Leuprorelin (leuprolide acetate) is a synthetic analogue of gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releas …
[Leuprorelin is innocent].
Hager T. Hager T. Ophthalmologe. 2021 Jun;118(6):614. doi: 10.1007/s00347-020-01189-0. Ophthalmologe. 2021. PMID: 32737574 German. No abstract available.
Clinical pharmacokinetics of depot leuprorelin.
Periti P, Mazzei T, Mini E. Periti P, et al. Clin Pharmacokinet. 2002;41(7):485-504. doi: 10.2165/00003088-200241070-00003. Clin Pharmacokinet. 2002. PMID: 12083977 Review.
Leuprorelin acetate is a synthetic agonist analogue of gonadotropin-releasing hormone. Continued leuprorelin administration results in suppression of gonadal steroid synthesis, resulting in pharmacological castration. ...Recently, an implant that delivers leupror …
Leuprorelin acetate is a synthetic agonist analogue of gonadotropin-releasing hormone. Continued leuprorelin administration re …
Leuprorelin acetate granulomas: case reports and review of the literature.
Yasukawa K, Sawamura D, Sugawara H, Kato N. Yasukawa K, et al. Br J Dermatol. 2005 May;152(5):1045-7. doi: 10.1111/j.1365-2133.2005.06341.x. Br J Dermatol. 2005. PMID: 15888168 Review.
Recently, depot formulations of leuprorelin acetate have been widely used. We report three patients who showed a granulomatous reaction after treatment using a leuprorelin acetate 3-month depot formulation. ...We have reviewed the previous reports of leuprorelin …
Recently, depot formulations of leuprorelin acetate have been widely used. We report three patients who showed a granulomatous reacti …
Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
Plosker GL, Brogden RN. Plosker GL, et al. Drugs. 1994 Dec;48(6):930-67. doi: 10.2165/00003495-199448060-00008. Drugs. 1994. PMID: 7533699 Review.
Leuprorelin (leuprolide acetate) is a gonadotrophin-releasing hormone (GnRH) analogue used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, endometriosis and precocious puberty. ...In children with central precocious pubert …
Leuprorelin (leuprolide acetate) is a gonadotrophin-releasing hormone (GnRH) analogue used to treat a wide range of sex hormon …
Clinical Studies Investigating the Use of Leuprorelin in Breast Cancer Patients from Asia.
Han W, Youn HJ. Han W, et al. Asian Pac J Cancer Prev. 2019 May 25;20(5):1475-1479. doi: 10.31557/APJCP.2019.20.5.1475. Asian Pac J Cancer Prev. 2019. PMID: 31127911 Free PMC article. Review.
Leuprorelin is a synthetic analogue of naturally occurring gonadotropin-releasing hormone. ...Leuprorelin-related adverse events included hot flush, mood swings and urogenital symptoms. ...
Leuprorelin is a synthetic analogue of naturally occurring gonadotropin-releasing hormone. ...Leuprorelin-related adverse even …
Clinical studies investigating the use of leuprorelin in Asian women with endometriosis: a review.
Osuga Y, Torng PL, Jeng CJ. Osuga Y, et al. J Obstet Gynaecol. 2019 Apr;39(3):291-296. doi: 10.1080/01443615.2018.1460584. Epub 2019 Jan 17. J Obstet Gynaecol. 2019. PMID: 30653368 Review.
Menopause is more common in women treated with leuprorelin. The bone mineral density is reduced in women treated with leuprorelin. There are limited studies investigating the use of leuprorelin for the treatment of endometriosis in Asian populations. However, …
Menopause is more common in women treated with leuprorelin. The bone mineral density is reduced in women treated with leuprorelin …
[Leuprorelin acetate depot].
Mashimo T. Mashimo T. Nihon Rinsho. 2000 Jul;58 Suppl:191-6. Nihon Rinsho. 2000. PMID: 11022712 Review. Japanese. No abstract available.
4,186 results